Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy: AIDS (London, England)

A Castagna, S Rusconi, R Gulminetti, S Bonora, G Mazzola, ME Quiros-Roldan, GV De Socio, N Ladisa, S Carosella, A Cattelan, S Di Giambenedetto, M Mena, A Poli, L Galli, A Riva, on behalf of the DAU Study Group

Research output: Contribution to journalArticle

Abstract

We evaluated the efficacy and safety of a two-drug regimen including dolutegravir (DTG) and unboosted atazanavir (uATV) in 151 HIV-1 infected patients with HIV-RNA of more than 50 copies/ml. During a median follow-up of 62 (42-97) weeks, two virological failures (1%) and 13 treatment discontinuations (9%) occurred; the 48-week probability of virological failure was 0.8% (95% confidence interval 0.2-5.6%). Switch to DTG + uATV may represent a boosting and transcriptase reverse inhibitors sparing otion in individuals with long exposure to antiretroviral therapy and risk of cardiovascular disease.
Original languageEnglish
Pages (from-to)1256-1260
Number of pages5
JournalAIDS
Volume33
Issue number7
DOIs
Publication statusPublished - 2019

    Fingerprint

Cite this

Castagna, A., Rusconi, S., Gulminetti, R., Bonora, S., Mazzola, G., Quiros-Roldan, ME., De Socio, GV., Ladisa, N., Carosella, S., Cattelan, A., Di Giambenedetto, S., Mena, M., Poli, A., Galli, L., Riva, A., & Group, O. B. O. T. DAU. S. (2019). Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy: AIDS (London, England). AIDS, 33(7), 1256-1260. https://doi.org/10.1097/QAD.0000000000002188